• Home
  1. Home
  2. Bortezomib-induced skin eruption
Scientific article
English

Bortezomib-induced skin eruption

Contributors

Sanchez-Politta, S.; Favet, Laurence; Kerl, K.; Dietrich, Pierre-Yves; Piguet, Vincent

Published in

Dermatology, vol. 216, no. 2, p. 156-158

Publication date

2008

Abstract

Bortezomib (Velcad) is a proteasome inhibitor recently developed and mainly used for the treatment of multiple myeloma. Bortezomib represents a novel class of drugs functioning as proteasome inhibitors. Skin complications of bortezomib treatment are very frequent but poorly characterized. We describe the case of a patient who developed erythematous and edematous plaques after treatment with bortezomib. This case illustrates one of the potential reactions associated with bortezomib administration and underlines the need to recognize and report cutaneous side effects of this new drug.

Keywords

  • Antineoplastic Agents/administration & dosage/adverse effects
  • Biopsy
  • Boronic Acids/administration & dosage/adverse effects
  • Diagnosis Differential
  • Dose-Response Relationship Drug
  • Drug Eruptions/etiology/pathology
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma/drug therapy
  • Pyrazines/administration & dosage/adverse effects
  • Skin/pathology

UNIGE affiliation entities

UNIGE research groups

Citation (ISO format)

SANCHEZ-POLITTA, S. et al. Bortezomib-induced skin eruption. In: Dermatology, 2008, vol. 216, n° 2, p. 156–158. doi: 10.1159/000111513

Main files (1)

Article (Accepted version)

Identifiers

Additional URL for this publication

http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000111513#AC

Journal ISSN

1018-8665
621views
0downloads

Technical informations

Creation

11/02/2009 13:58:00

First validation

11/02/2009 13:58:00

Update

14/03/2023 15:00:13

Status update

14/03/2023 15:00:13

Last indexation

29/10/2024 11:08:01
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated